Demyelinating events in early multiple sclerosis have inherent severity and recovery
- PMID: 19221292
- PMCID: PMC2677540
- DOI: 10.1212/01.wnl.0000342458.39625.91
Demyelinating events in early multiple sclerosis have inherent severity and recovery
Abstract
Background: It is unclear whether the severity of and recovery from the initial demyelinating event (IDE) are recapitulated in subsequent multiple sclerosis (MS) relapses. We sought to identify the factors associated with relapse severity and recovery and to evaluate whether events have inherent severity or recovery.
Methods: Patients seen at the UCSF MS Clinic within 1 year of disease onset were identified from a prospective database. Ordinal logistic regression was used to analyze predictors of three-level categorizations of event severity and recovery.
Results: We identified 330 patients with MS or clinically isolated syndrome; 152 had a second event and 63 had a third event. Nonwhite and younger patients were at an increased risk of more severe demyelinating events. A severe prior event predicted a substantial increase in the odds of being above any given severity cutoff for a severe subsequent event (for second event severity, odds ratio [OR] = 5.62, 95% confidence interval [CI] [2.39, 13.26], p < 0.0001; for third event severity, OR = 6.74, 95% CI [1.67, 27.18], p = 0.007). Similarly, poor recovery of the IDE predicted poor second event recovery (OR = 5.28, 95% CI [1.95, 14.25], p = 0.001), while fair or poor second event recovery predicted about a 5- or 13-fold increase in the odds of poor third event recovery. A more severe event also predicted a substantial increase in the odds of poor recovery.
Conclusions: Patients with severe presentation and poor recovery at disease onset continue on a similar trajectory with subsequent demyelinating events. Whether genetic or other biologic factors are responsible for this pattern remains to be determined.
Similar articles
-
Are initial demyelinating event recovery and time to second event under differential control?Neurology. 2006 Sep 12;67(5):809-13. doi: 10.1212/01.wnl.0000234031.30756.a0. Neurology. 2006. PMID: 16966542
-
Relapse severity and recovery in early pediatric multiple sclerosis.Mult Scler. 2012 Jul;18(7):1008-12. doi: 10.1177/1352458511431725. Epub 2011 Dec 19. Mult Scler. 2012. PMID: 22183939
-
Clinical predictors of early second event in patients with clinically isolated syndrome.J Neurol. 2009 Jul;256(7):1061-6. doi: 10.1007/s00415-009-5063-0. Epub 2009 Mar 1. J Neurol. 2009. PMID: 19252775 Free PMC article.
-
Acute inflammatory demyelinating optic neuritis: evidence-based visual and neurological considerations.Neurologist. 2008 Jul;14(4):207-23. doi: 10.1097/NRL.0b013e31816f27fe. Neurologist. 2008. PMID: 18617847 Review.
-
MRI features associated with rapid disease activity in clinically isolated syndrome patients at high risk for multiple sclerosis.Mult Scler Relat Disord. 2020 Jun;41:101985. doi: 10.1016/j.msard.2020.101985. Epub 2020 Feb 6. Mult Scler Relat Disord. 2020. PMID: 32087591 Review.
Cited by
-
Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.PLoS One. 2013 Oct 9;8(10):e75416. doi: 10.1371/journal.pone.0075416. eCollection 2013. PLoS One. 2013. PMID: 24130709 Free PMC article.
-
Autoimmune diseases and reproductive aging.Clin Immunol. 2013 Nov;149(2):251-64. doi: 10.1016/j.clim.2013.02.010. Epub 2013 Feb 28. Clin Immunol. 2013. PMID: 23522436 Free PMC article. Review.
-
Assessing relapse in multiple sclerosis questionnaire: results of a pilot study.Mult Scler Int. 2013;2013:470476. doi: 10.1155/2013/470476. Epub 2013 May 26. Mult Scler Int. 2013. PMID: 23766909 Free PMC article.
-
Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.Eur J Neurol. 2018 May;25(5):762-767. doi: 10.1111/ene.13594. Epub 2018 Mar 6. Eur J Neurol. 2018. PMID: 29431876 Free PMC article.
-
Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability.Mult Scler J Exp Transl Clin. 2021 May 28;7(2):20552173211015503. doi: 10.1177/20552173211015503. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 34104471 Free PMC article.
References
-
- Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770–782. - PubMed
-
- Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population based cohort: a 10-year follow-up study. Neurology 2004;62:51–59. - PubMed
-
- Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990;113:1597–1628. - PubMed
-
- Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study: 3: multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045–1056. - PubMed
-
- Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999;168:96–106. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical